Actavis Will Keep Selling Alzheimer's Drug In U.S. For 60 Days

(Reuters) - Actavis Plc has reached an agreement with New York's attorney general to keep selling a top Alzheimer's drug for 60 days so U.S. patients will not be forced to switch to a newer, more expensive form of the drug with additional patent protection.

The accord was announced in U.S. District Court in Manhattan on Wednesday in response to New York Attorney General Eric Schneiderman's antitrust case against the pharmaceutical firm.

The lawsuit, filed on Sept. 15, accuses the company and its New York-based subsidiary, Forest Laboratories, of scheming to reduce generic competition for its Alzheimer's medication.

Help employers find you! Check out all the jobs and post your resume.